Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An exploratory study comparing the efficacy and safety of alpha-interferon combined with anti-PD-1 monoclonal antibody as an adjuvant therapy in HCC patients with portal vein tumor thrombus after hepatectomy

Next Previous
Search
Trial Profile

An exploratory study comparing the efficacy and safety of alpha-interferon combined with anti-PD-1 monoclonal antibody as an adjuvant therapy in HCC patients with portal vein tumor thrombus after hepatectomy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tislelizumab (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 14 Dec 2023 New trial record
    • 24 Oct 2023 Status changed from not yet recruiting to recruiting, according to Results presented at the 48th European Society for Medical Oncology Congress.
    • 24 Oct 2023 Results (n=38) presented at the 48th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top